Table of contents

1. Outlook FY 2019

2. Financial performance Q3 2019
Outlook 2019 confirmed
Intensified self-help compensates production constraints and weaker environment

- Market environment
  - Ongoing **challenging market environment** mirrored in tight Q3 businesses performance

- Production constraints in Performance Materials
  - Production constraints additionally weigh on H2 earnings

- Self-help measures
  - Self-help measures intensified: **SG&A program ahead of plan**; additional **contingency measures** implemented

**EBITDA guidance 2019 confirmed:**
“at least stable adj. EBITDA” (FY 2018: €2,150 m)
SG&A program ahead of plan – additional contingency measures implemented for H2 2019

- Additional contingencies of +€20 m
  - Hiring discipline (free positions filled internally)
  - Travel restrictions (e.g. more digital meetings)
  - Reduced expenditure on external consultants
  - Maintenance (energy & plant management)
  - Salary components

+€40 m in H2 2019
(thereof €25 m in Q4)
Q4 EBITDA expected ~ €500 m
Reduced Q4 seasonality supported by license fees & cost savings

(Adj. EBITDA in € m)

<table>
<thead>
<tr>
<th>9M 2019</th>
<th>1,647</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal Q4</td>
<td></td>
</tr>
<tr>
<td>Per. Materials</td>
<td></td>
</tr>
<tr>
<td>License proceeds</td>
<td></td>
</tr>
<tr>
<td>Higher savings</td>
<td></td>
</tr>
<tr>
<td>Outlook 2019</td>
<td></td>
</tr>
</tbody>
</table>

- Normal Q4 earnings (= qoq seasonality of ~20% (after MMA sale))
- Lower qoq impact from production constraints in Performance Materials
- License proceeds of ~€40 m from two projects in Active Oxygens
- SG&A program ahead of plan; additional contingency measures implemented (~ €25 m in Q4)

"at least stable" (2018: €2,150 m)
Outlook 2019: Free Cashflow
Strong improvement both in FCF and cash conversion – further upside in 2020

“Free cash flow of around €700 m” (FY 2018: €526 m)

- Significantly higher FCF: ~€700 m
- Strict working capital management
- High capex discipline
- Support from CTA reimbursement

Cash conversion rate
- above 30% in 2019
- further upside for 2020

1. Extraordinary carve-out taxes of €200-220 m (related to MMA divestment) not considered in 2019 outlook
Table of contents

1. Outlook FY 2019

2. Financial performance Q3 2019
Free Cash Flow 9M 2019
On track to significantly higher FCF in FY 2019

Free Cash Flow 9M 2019 (in €m, continuing operations)

- FCF improved by €93 m in 9M 2019
- … despite lower EBIT
- … and higher bonus payments (for fiscal 2018)
- Operating cash flow in 9M benefitting from lower cash outflows for NWC and pensions (CTA effect)
- Capex discipline: reduction by €81 m yoy

1. Extraordinary carve-out taxes of €128 m (related to MMA divestment) not considered
Successful efficiency measures reflected in improved financial metrics

**Overhead costs (9M 2019)**
- Corporate/Other segment >€50 m below prior year
- All quarters with tangibly lower cost base yoy

**Admin expenses (9M 2019)**

<table>
<thead>
<tr>
<th>(in € m)</th>
<th>9M 18</th>
<th>9M 19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corporate/Other segment</td>
<td>445</td>
<td>419</td>
</tr>
<tr>
<td>-26</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

New indication for Corp/Other segment in FY 2019:
“Tangibly less negative than 2018”

Further acceleration of savings in 2019

- €26 m (despite usual factor cost increases)
Resource Efficiency
Sequentially stable earnings in an unchanged challenging market environment

<table>
<thead>
<tr>
<th>Sales (in € m)</th>
<th>Adj. EBITDA (in € m) / margin (in %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q3 18 1,425</td>
<td>Q3 18 335</td>
</tr>
<tr>
<td>Q4 18 1,402</td>
<td>Q4 18 256</td>
</tr>
<tr>
<td>Q1 19 1,438</td>
<td>Q1 19 330</td>
</tr>
<tr>
<td>Q2 19 1,445</td>
<td>Q2 19 326</td>
</tr>
<tr>
<td>Q3 19 1,414</td>
<td>Q3 19 322</td>
</tr>
</tbody>
</table>

-1%  -4%

Q3 19 vs. Q3 18
Volume -3% ▼ | Price +1% ↑ | FX +1% ↑ | Other 0%  

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%

-3%  +1%  +1%  0%
Nutrition & Care
Solid operational performance in resilient end markets

Sales (in € m)

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 18</th>
<th>Q4 18</th>
<th>Q1 19</th>
<th>Q2 19</th>
<th>Q3 19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>1,167</td>
<td>1,172</td>
<td>1,149</td>
<td>1,131</td>
<td>1,138</td>
</tr>
<tr>
<td>% Change</td>
<td>-2%</td>
<td>0%</td>
<td>-2%</td>
<td>-1%</td>
<td>-1%</td>
</tr>
</tbody>
</table>

Adj. EBITDA (in € m) / margin (in %)

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 18</th>
<th>Q4 18</th>
<th>Q1 19</th>
<th>Q2 19</th>
<th>Q3 19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjusted EBITDA</td>
<td>212</td>
<td>167</td>
<td>180</td>
<td>190</td>
<td>188</td>
</tr>
<tr>
<td>Margin</td>
<td>18.2</td>
<td>14.2</td>
<td>15.7</td>
<td>16.8</td>
<td>16.5</td>
</tr>
<tr>
<td>% Change</td>
<td>-11%</td>
<td>0%</td>
<td>2%</td>
<td>0%</td>
<td>1%</td>
</tr>
</tbody>
</table>

- High demand in Animal Nutrition continues to be neutralized by planned shift from bulk to specialty products (in Care Solutions and for Veramaris JV)
- Robust contribution from Care Solutions and accelerating earnings in Health Care (FY 2019 back-end loaded)
- Methionine with ongoing strong volumes, sequentially slightly lower prices
- Successful implementation of efficiency programs throughout 2019 mitigate negative methionine price effect of > €100 m
Performance Materials
Difficult quarter due to limited raw material availability and unexpected outage

- Difficult market environment for petrochemical derivatives continuing. Additionally, C4 business impacted by limited raw material availability and unexpected outage (BD-plant in Antwerp) (combined EBITDA impact of ~€20 m in Q3)
- Prices down mainly due to yoy lower Butadiene spread
- Q4 earnings will be impacted by limited product availability for INA and DINP (compressor failure in C4 plant in Marl). Production constraints expected to be solved by mid-November. Expected impact on EBITDA in Q4: ~€10 m
Performance Materials
Supply issues and production constraints throughout the year

- Integrated production set-up based on supply of crack C4 from crackers in Marl & Antwerp
- Evonik’s advantage to make complete use of all C4 fractions
- High plant utilization crucial for segment earnings

Challenges 2019

- Q1 with limited raw material availability in Marl (supplier shutdown)
  - Impact on EBITDA in Q1: ~€10 m

- Q3 with limited raw material availability in Antwerp (supplier shutdown) and unexpected turnaround in Antwerp (BD-plant)
  - Impact on EBITDA in Q3: ~€20 m

- Q4 impacted by limited product availability due to compressor failure in Marl. Production constraints expected to be solved by mid-November.
  - Expected impact on EBITDA in Q4: ~€10 m
Save the date

Capital Markets Day

London
1 April 2020

Details and invitation to follow shortly
Additional indications for 2019

- Synergies from acquisitions (APD & Huber Silica)
  Additional synergies of ~€30 m (total synergies: ~€70 m)

- PeroxyChem
  Not included in outlook

- ROCE
  Slightly below (previously: above) cost of capital (10.0% before taxes) and below (previously: around) the level of 2018 (10.2%)

- Capex
  ~€900 m (previously: €950 m; 2018: €969 m)

- EUR/USD
  1.15 EUR/USD (2018: 1.18 EUR/USD)

- EUR/USD sensitivity¹
  +/-1 USD cent = +/- ~€8 m adj. EBITDA (FY basis)

- Adj. EBITDA Services
  Slightly above the level of 2018 (previously: around the level of 2018; 2018: €100 m)

- Adj. EBITDA Corporate / Others
  Tangibly less negative than 2018 (previously: slightly less negative (2018: -€283 m))

- Adj. D&A
  ~€900 m (2018: €789 m); increase mainly IFRS 16-related

- Adj. net financial result²
  ~€190 m (2018: -€151 m); increase partly IFRS 16-related

- Adj. tax rate
  Around the level of 2018 (2018: 23%); 2018 & 2019 benefit from US tax reform & MMA-related deferred tax assets, normalization of adj tax rate to ~28% expected from 2020 onwards

¹. Including transaction effects (after hedging) and translation effects; before secondary / market effects | ². Guidance for "Adj. net financial result" subject to interest rate fluctuations which influence discounting effects on provisions
### Modelling support: Summary of Q3 & Q4 effects

<table>
<thead>
<tr>
<th></th>
<th>Q3 effect</th>
<th>Q4 effect (expected)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Performance Materials¹</td>
<td>-20</td>
<td>-10</td>
<td>-30</td>
</tr>
<tr>
<td>Licenses RE</td>
<td></td>
<td>+40</td>
<td>+40</td>
</tr>
<tr>
<td>SG&amp;A ahead of plan</td>
<td>+10</td>
<td>+10</td>
<td>+20</td>
</tr>
<tr>
<td>Add. contingency measures</td>
<td>+5</td>
<td>+15</td>
<td>+20</td>
</tr>
</tbody>
</table>

¹ Limited raw material availability and unexpected outage Butadiene plant in Q3; limited product availability (compressor failure) in Q4
Outlook 2019:
EBITDA outlook confirmed, sales now expected slightly lower

“slightly lower sales”
(FY 2018: €13,267 m)

- With regards to the challenging macro environment we revised our sales outlook for 2019
- Sales on group level are expected to be slightly below prior year’s level
  (previously: at least stable)

“at least stable adj. EBITDA”
(FY 2018: €2,150 m)

- EBITDA guidance on group level confirmed
  - Update on segment guidance:
    - Nutrition & Care slightly lower (confirmed)
    - Resource Efficiency slightly higher (confirmed)
    - Performance Materials lower
      (previously: around level of last year)
    - Services and Corporate/Other with tangibly lower cost base
Free Cash Flow 9M & FY 2019
Carve-out taxes related to MMA divestment to be fully paid in Q3 & Q4 2019

Free Cash Flow 9M 2019
(in €m, continuing operations)

Free Cash Flow FY 2019E
(in €m, continuing operations)

<table>
<thead>
<tr>
<th></th>
<th>FCF incl. carve-out taxes</th>
<th>Carve-out taxes</th>
<th>FCF excl. carve-out taxes</th>
</tr>
</thead>
<tbody>
<tr>
<td>9M 2019</td>
<td>289</td>
<td>128</td>
<td>417</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>FCF incl. carve-out taxes</th>
<th>Carve-out taxes</th>
<th>FCF excl. carve-out taxes</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2019E</td>
<td>200-220†</td>
<td>~700</td>
<td></td>
</tr>
</tbody>
</table>

1. Carve-out taxes expectation for FY 2019 €200 m– €220 m (previously: €260 m)
Financial highlights Q3 2019
Solid performance despite ongoing macro headwinds

**Sales**
(in € m)

<table>
<thead>
<tr>
<th></th>
<th>Q3 18</th>
<th>Q3 19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>-3%</td>
<td></td>
</tr>
<tr>
<td>Price</td>
<td>-2%</td>
<td></td>
</tr>
<tr>
<td>FX</td>
<td>+2%</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>0%</td>
<td></td>
</tr>
</tbody>
</table>

**Adj. EBITDA**
(in € m)

<table>
<thead>
<tr>
<th></th>
<th>Q3 18</th>
<th>Q3 19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>-3%</td>
<td></td>
</tr>
<tr>
<td>Price</td>
<td>-2%</td>
<td></td>
</tr>
<tr>
<td>FX</td>
<td>+2%</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>0%</td>
<td></td>
</tr>
</tbody>
</table>

**Adj. EPS**
(in €)

<table>
<thead>
<tr>
<th></th>
<th>Q3 18</th>
<th>Q3 19</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.66</td>
<td></td>
<td>0.42</td>
</tr>
</tbody>
</table>

**Net financial debt position**
(in € m)

-4,081 to -1,734
30 June 2019 to 30 Sep. 2019

+€2.3 bn
Services and Corporate / Others

- 9M run rate of €99 m in line with new guidance (“slightly above the level of 2018”; 2018: €100 m)
- YTD positive impact from cost savings and IFRS 16

- Strict cost discipline clearly visible in Corporate/Others segment with positive effects from SG&A as well as additional contingency measures
Resource Efficiency
Q3 2019 Business Line comments

**Sales (in € m)**

<table>
<thead>
<tr>
<th></th>
<th>Q3 18</th>
<th>Q2 19</th>
<th>Q3 19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adj. EBITDA / margin (in %)</td>
<td>1.425</td>
<td>1.445</td>
<td>1.414</td>
</tr>
</tbody>
</table>

**Adj. EBITDA (in € m)**

<table>
<thead>
<tr>
<th></th>
<th>Q3 18</th>
<th>Q2 19</th>
<th>Q3 19</th>
</tr>
</thead>
<tbody>
<tr>
<td>335</td>
<td>326</td>
<td>322</td>
<td></td>
</tr>
<tr>
<td>23.5</td>
<td>22.6</td>
<td>22.8</td>
<td></td>
</tr>
</tbody>
</table>

**Crosslinkers:** Continued good demand for composites applications from the wind energy market in China. Earnings supported by favourable product mix and raw material prices (Acetone).

**High Performance Polymers:** Another good quarter, innovations like membranes and 3D printing applications supported demand for polymers.

**Silica:** Tire business holding up well due to intact replacement market, slower demand for industry-linked applications like sealants and silicones for automotive.

**Coating Additives:** Weaker due to ongoing macro slowdown, especially in container coatings and automotive.
**Nutrition & Care**

Q3 2019 Business Line comments

**Sales (in € m)**

<table>
<thead>
<tr>
<th></th>
<th>Q3 18</th>
<th>Q2 19</th>
<th>Q3 19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>1,167</td>
<td>1,131</td>
<td>1,138</td>
</tr>
</tbody>
</table>

-2%  

<table>
<thead>
<tr>
<th></th>
<th>Adj. EBITDA (in € m) / margin (in %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q3 18</td>
<td>212 / 18.2</td>
</tr>
<tr>
<td>Q2 19</td>
<td>190 / 16.8</td>
</tr>
<tr>
<td>Q3 19</td>
<td>188 / 16.5</td>
</tr>
</tbody>
</table>

**Care Solutions**: Good performance of Cosmetic Solutions and Active Ingredients in 2019. Overall lower volumes due to planned upgrade in product mix.

**Health Care**: As anticipated, business in Q3 picking up significantly (qoq). Also Q4 expected strong due to back-end loaded phasing of earnings. Overall, FY 2019 with yoy stable earnings (due to end of large legacy contract).

**Comfort & Insulation**: Subdued business in auto-related applications more than compensated by higher demand from consumer durables and isolation end-markets.

**Baby Care**: Improvement from a low base continuing. Self-help measures with positive effect on margin as well as yoy more favorable time-lag effects from raw material prices.

**Animal Nutrition**: Methionine with ongoing strong volumes, sequentially slightly lower prices.

5 November 2019 | Evonik Q3 2019 Earnings Conference Call
# Performance Materials
## Q3 2019 Business Line comments

### Sales (in € m)

<table>
<thead>
<tr>
<th></th>
<th>Q3 18</th>
<th>Q2 19</th>
<th>Q3 19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Value</td>
<td>591</td>
<td>553</td>
<td>475</td>
</tr>
</tbody>
</table>

-20% decrease from Q2 19 to Q3 19.

### Adj. EBITDA (in € m) / margin (in %)

<table>
<thead>
<tr>
<th></th>
<th>Q3 18</th>
<th>Q2 19</th>
<th>Q3 19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Value</td>
<td>63</td>
<td>74</td>
<td>47</td>
</tr>
<tr>
<td>Margin</td>
<td>10.7</td>
<td>13.4</td>
<td>9.9</td>
</tr>
</tbody>
</table>

-25% decrease from Q2 19 to Q3 19.

### Performance Intermediates:
- Lower volumes in PI due to unexpected plant outage in Antwerp in combination with limited raw material availability.
- Prices down mainly due to yoy noticeably lower Butadiene spread.
- Good MTBE development to persist in Q3 due to strong gasoline demand in combination with cracker outages. Contrarily, globally weaker market for petrochemical derivatives (INA, Butene-1).

### Functional Solutions:
- Solid performance continues. Divestment of non-core Jayhawk site (October 2018) compensated by continued high demand from Biodiesel market for Alkoxides.
- Earnings also supported by cost advantages from merger of two BL’s (less admin costs and more efficient supply chain).
SG&A 2020 – progressing faster than expected
Full saving potential already realized by end of 2020

As announced

(SG&A savings p.a. in €m)

<table>
<thead>
<tr>
<th>Year</th>
<th>Savings (€m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>50</td>
</tr>
<tr>
<td>2019</td>
<td>50</td>
</tr>
<tr>
<td>2020</td>
<td>80</td>
</tr>
</tbody>
</table>

New phasing

(SG&A savings p.a. in €m)

<table>
<thead>
<tr>
<th>Year</th>
<th>Savings (€m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>50</td>
</tr>
<tr>
<td>2019</td>
<td>70 (±20)</td>
</tr>
<tr>
<td>2020</td>
<td>90 (±20)</td>
</tr>
</tbody>
</table>

*€200 m savings potential by end of 2021*

*€200 m savings already realized by end of 2020*
Net financial debt position development Q3 2019 (continued operations)

(in € m)

1. Contractual agreements such as the final valuation of net working capital after closing will result in changes in the purchase price into the first half of 2020
## Development of net debt and leverage over time

From Q3 2019 onwards excluding discontinued operations

(in € m)

<table>
<thead>
<tr>
<th>Year</th>
<th>Net debt</th>
<th>Pension provisions</th>
<th>Total leverage¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>6,840</td>
<td>3,023</td>
<td>2.8x</td>
</tr>
<tr>
<td>2018</td>
<td>6,639</td>
<td>2,907</td>
<td>2.5x</td>
</tr>
<tr>
<td>Q1 19</td>
<td>7,467</td>
<td>3,437</td>
<td>2.8x</td>
</tr>
<tr>
<td>Q2 19</td>
<td>8,499</td>
<td>4,093</td>
<td>3.4x</td>
</tr>
<tr>
<td>Q3 19</td>
<td>6,374</td>
<td>1,734</td>
<td>3.0x</td>
</tr>
</tbody>
</table>

- Net financial debt decreased as per Q3 2019 (vs Q2) mainly due to proceeds from the MMA disposal
- Net financial debt leverage at 0.7x as per Q3 2019
- Pension provisions increased by ~€0.2 bn (despite €0.6 bn pension transfer from MMA disposal) based on a sharp decline of the German discount rate to 1.0%
- Pension provisions are partly balanced by corresponding deferred tax assets of ~€1.6 bn as per Q3 2019
- Almost 75% of total net debt consists of long-dated pension obligations (> 15 years)

1. Total leverage defined as (net financial debt - 50% hybrid bond + pension provisions) / adj. EBITDA LTM  
2. Calculated annually  
3. Continuing operations (excluding MMA)
Adjusted income statement Q3 2019

<table>
<thead>
<tr>
<th>in € m</th>
<th>Q3 2018</th>
<th>Q3 2019</th>
<th>△ in %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>3,347</td>
<td>3,232</td>
<td>-3</td>
</tr>
<tr>
<td>Adj. EBITDA</td>
<td>579</td>
<td>543</td>
<td>-6</td>
</tr>
<tr>
<td>Adj. depreciation &amp; amortization</td>
<td>-203</td>
<td>-250</td>
<td></td>
</tr>
<tr>
<td>Adj. EBIT</td>
<td>376</td>
<td>293</td>
<td>-22</td>
</tr>
<tr>
<td>Adj. net financial result</td>
<td>-37</td>
<td>-63</td>
<td></td>
</tr>
<tr>
<td>D&amp;A on intangible assets</td>
<td>33</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td>Adj. income before income taxes</td>
<td>372</td>
<td>265</td>
<td>-29</td>
</tr>
<tr>
<td>Adj. income tax</td>
<td>-60</td>
<td>-65</td>
<td></td>
</tr>
<tr>
<td>Adj. income after taxes</td>
<td>312</td>
<td>200</td>
<td>-36</td>
</tr>
<tr>
<td>Adj. non-controlling interests</td>
<td>-5</td>
<td>-5</td>
<td></td>
</tr>
<tr>
<td>Adj. net income</td>
<td>307</td>
<td>195</td>
<td>-36</td>
</tr>
<tr>
<td>Adj. earnings per share</td>
<td>0.66</td>
<td>0.42</td>
<td>-36</td>
</tr>
<tr>
<td>Adjustments</td>
<td>-12</td>
<td>-74</td>
<td></td>
</tr>
</tbody>
</table>

Adj. depreciation & amortization:
- Increase in D&A mainly due to IFRS 16 and first depreciation of new methionine plant

Adj. net financial result:
- Overall lower interest rate level leads to:
  - Negative interest on short-term securities (higher expenses)
  - Higher interest expenses as a result from discounting of long-term provisions

Adj. tax rate:
- Q3 2019 adj. tax rate of 25%, 9M 2019 at 22%, in-line with full year guidance (around 23%)

Adjustments:
- Restructuring -€6 m: SG&A 2020 related
- Impairments -€34 m: for coal power plant in Marl (Germany), which is replaced by natural gas power plant in 2022
- Acquisitions/divestments -€17 m: related to M&A transactions
Cash flow statement Q3 2019

<table>
<thead>
<tr>
<th>Item</th>
<th>Q3 2018</th>
<th>Q3 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Income before financial result and income taxes</td>
<td>364</td>
<td>219</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>198</td>
<td>286</td>
</tr>
<tr>
<td>Δ Net working capital</td>
<td>-48</td>
<td>+3</td>
</tr>
<tr>
<td>Change in provisions for pensions &amp; other post-employment benefits</td>
<td>-54</td>
<td>-34</td>
</tr>
<tr>
<td>Change in other provisions</td>
<td>+73</td>
<td>+46</td>
</tr>
<tr>
<td>Change in miscellaneous assets/liabilities</td>
<td>+37</td>
<td>+6</td>
</tr>
<tr>
<td>Cash outflows from income taxes</td>
<td>-68</td>
<td>0</td>
</tr>
<tr>
<td>Extraordinary carve-out taxes related to MMA divestment</td>
<td>0</td>
<td>-128</td>
</tr>
<tr>
<td>Others</td>
<td>-2</td>
<td>5</td>
</tr>
<tr>
<td><strong>Cash flow from operating activities (continuing ops.)</strong></td>
<td>500</td>
<td>403</td>
</tr>
</tbody>
</table>

- Cash outflows for investment in intangible assets, pp&e             -222    -210
- FCF (excl. extraordinary carve-out taxes related to MMA divestment) 278     321
- Cash inflows from divestment of businesses                           0       2.189
- **Cash flow from investing activities (continuing ops.)**           -235    757
- **Cash flow from financing activities (continuing ops.)**           -128    -219

1. Contractual agreements such as the final valuation of net working capital after closing may result in changes in the purchase price into the first half of 2020

**CF from operating activities**
- Higher D&A mainly due to IFRS 16, first depreciation of new methionine plant and impairment on the coal power plant in Marl
- Stable NWC due to strict NWC management
- Lower cash-out for pension provisions mirrors positive effect from CTA reimbursement in 2019
- Cash out for taxes: No cash-out for income taxes in Q3 due to phasing in tax payments over the year and higher prepayments; Q3 2019 with €128 m of carve-out taxes related to the MMA divestment (€200 - 220 m expected for FY 2019)

**CF from investing activities**
- A part of MMA proceeds of €2.21 bn immediately invested in securities resulting in CF from investing activities of €757 m
## Segment overview by quarter – continuing operations

<table>
<thead>
<tr>
<th>Sales (in € m)</th>
<th>Q1/18</th>
<th>Q2/18</th>
<th>Q3/18</th>
<th>Q4/18</th>
<th>FY 2018</th>
<th>Q1/19</th>
<th>Q2/19</th>
<th>Q3/19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nutrition &amp; Care</td>
<td>1,119</td>
<td>1,189</td>
<td>1,167</td>
<td>1,172</td>
<td>4,646</td>
<td>1,149</td>
<td>1,131</td>
<td>1,138</td>
</tr>
<tr>
<td>Resource Efficiency</td>
<td>1,402</td>
<td>1,478</td>
<td>1,425</td>
<td>1,402</td>
<td>5,708</td>
<td>1,438</td>
<td>1,445</td>
<td>1,414</td>
</tr>
<tr>
<td>Performance Materials</td>
<td>563</td>
<td>573</td>
<td>591</td>
<td>506</td>
<td>2,233</td>
<td>520</td>
<td>553</td>
<td>475</td>
</tr>
<tr>
<td>Services</td>
<td>160</td>
<td>169</td>
<td>161</td>
<td>175</td>
<td>664</td>
<td>174</td>
<td>171</td>
<td>196</td>
</tr>
<tr>
<td>Corporate / Others</td>
<td>3</td>
<td>4</td>
<td>3</td>
<td>6</td>
<td>16</td>
<td>6</td>
<td>6</td>
<td>9</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adj. EBITDA (in € m)</th>
<th>Q1/18</th>
<th>Q2/18</th>
<th>Q3/18</th>
<th>Q4/18</th>
<th>FY 2018</th>
<th>Q1/19</th>
<th>Q2/19</th>
<th>Q3/19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nutrition &amp; Care</td>
<td>209</td>
<td>222</td>
<td>212</td>
<td>167</td>
<td>810</td>
<td>180</td>
<td>190</td>
<td>188</td>
</tr>
<tr>
<td>Resource Efficiency</td>
<td>324</td>
<td>367</td>
<td>335</td>
<td>256</td>
<td>1,283</td>
<td>330</td>
<td>326</td>
<td>322</td>
</tr>
<tr>
<td>Performance Materials</td>
<td>60</td>
<td>71</td>
<td>63</td>
<td>46</td>
<td>239</td>
<td>53</td>
<td>74</td>
<td>47</td>
</tr>
<tr>
<td>Services</td>
<td>35</td>
<td>25</td>
<td>39</td>
<td>0</td>
<td>100</td>
<td>31</td>
<td>36</td>
<td>32</td>
</tr>
<tr>
<td>Evonik Group</td>
<td>554</td>
<td>616</td>
<td>579</td>
<td>402</td>
<td>2,150</td>
<td>539</td>
<td>566</td>
<td>543</td>
</tr>
</tbody>
</table>
## Upcoming IR events

<table>
<thead>
<tr>
<th>Conferences &amp; Roadshows</th>
<th>Upcoming Events &amp; Reporting Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>6 November 2019</strong> Roadshow, Frankfurt</td>
<td><strong>4 March 2020</strong> Q4/FY 2019 reporting</td>
</tr>
<tr>
<td><strong>13 November 2019</strong> UBS European Conference, London</td>
<td><strong>7 May 2020</strong> Q1 2020 reporting</td>
</tr>
<tr>
<td><strong>14 November 2019</strong> Roadshow, Dublin</td>
<td><strong>4 August 2020</strong> Q2 2020 reporting</td>
</tr>
<tr>
<td><strong>25 November 2019</strong> UBS Senior Investor Day, Munich</td>
<td><strong>3 November 2020</strong> Q3 2020 reporting</td>
</tr>
<tr>
<td><strong>28 November</strong> Kepler Cheuvreux One-Stop-Shop, Amsterdam</td>
<td></td>
</tr>
<tr>
<td><strong>2 December 2019</strong> Berenberg European Corporate Conf., London Pennyhill</td>
<td></td>
</tr>
<tr>
<td><strong>3 December 2019</strong> Bank of America Chemicals Conference, London</td>
<td></td>
</tr>
<tr>
<td><strong>4 December 2019</strong> Societe Generale Premium Review, Paris</td>
<td></td>
</tr>
<tr>
<td><strong>14-15 January 2020</strong> Commerzbank German Investment Seminar, New York</td>
<td></td>
</tr>
<tr>
<td><strong>16 January 2020</strong> Baader German Corporate Day, Toronto</td>
<td></td>
</tr>
<tr>
<td><strong>17 January 2020</strong> Roadshow Montreal</td>
<td></td>
</tr>
<tr>
<td><strong>20-21 January 2020</strong> Kepler Cheuvreux German Corporate Conference, Frankfurt</td>
<td></td>
</tr>
</tbody>
</table>
# Evonik Investor Relations team

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tim Lange</td>
<td>Head of Investor Relations</td>
<td>+49 201 177 3150 <a href="mailto:tim.lange@evonik.com">tim.lange@evonik.com</a></td>
</tr>
<tr>
<td>Ina Gährken</td>
<td>Investor Relations Manager</td>
<td>+49 201 177 3142 <a href="mailto:ina.gaehrken@evonik.com">ina.gaehrken@evonik.com</a></td>
</tr>
<tr>
<td>Joachim Kunz</td>
<td>Investor Relations Manager</td>
<td>+49 201 177 3148 <a href="mailto:joachim.kunz@evonik.com">joachim.kunz@evonik.com</a></td>
</tr>
<tr>
<td>Janine Kanotowsky</td>
<td>Team Assistant</td>
<td>+49 201 177 3146 <a href="mailto:janine.kanotowsky@evonik.com">janine.kanotowsky@evonik.com</a></td>
</tr>
<tr>
<td>Kai Kirchhoff</td>
<td>Investor Relations Manager</td>
<td>+49 201 177 3145 <a href="mailto:kai.kirchhoff@evonik.com">kai.kirchhoff@evonik.com</a></td>
</tr>
<tr>
<td>Fabian Schwane</td>
<td>Investor Relations Manager</td>
<td>+49 201 177 3149 <a href="mailto:fabian.schwane@evonik.com">fabian.schwane@evonik.com</a></td>
</tr>
</tbody>
</table>
Disclaimer

In so far as forecasts or expectations are expressed in this presentation or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.